Article

Q&A Interview: Navigating the launch of ATMPs in Europe

European Union Flag_shutterstock_405765847
Fill out the form below to watch the interview
European Union Flag_shutterstock_405765847
In the rapidly evolving landscape of Advanced Therapy Medicinal Products (ATMPs) in Europe, staying abreast of regulatory changes and market access dynamics is crucial for developers aiming to bring innovative therapies to patients in need.  

Considering the imminent impact of the EU Health Technology Assessment (HTA) on ATMPs and oncology drugs, starting January 2025, Cencora experts Lung-I Cheng, Vice President and Head of Cell and Gene Therapy, and Herbert Altmann, Vice President of Market Access and Healthcare Consulting, shed light on the upcoming shifts in regulation and the strategies essential for successful navigation. 

The EU HTA regulation and Joint Clinical Assessment (JCA) process aim to eradicate access disparities, streamline procedures, and foster innovation within the pharmaceutical sector. Given that ATMPs encounter distinct challenges in evidence generation and market access, understanding these changes is paramount. 
European Union Flag_shutterstock_405765847


Providing an overview of the European Union's new health technology assessment (HTA) regulation and Joint Clinical Assessment (JCA) process, Cheng and Altmann discuss the overarching objectives of EU HTA-R and delve into the key criteria used to assess pharmaceuticals in Europe, variations across member states, and the pivotal role of HTAs in determining reimbursement and market accessibility, in particular for ATMPs. 

ATMPs pose a unique challenge due to their genetic-, tissue-, or cell-based nature. As treatments primarily aimed at rare diseases with European Medicine Agency (EMA) approval status, they face hurdles related to clinical trial design complexities leading to discrepancies in value compared to standard care options. The high cost associated with ATMPs further complicates pricing decisions and raises concerns about healthcare system affordability. 

Watch the interview to gain a comprehensive overview of the evolving regulatory landscape and better understand the importance of proactive planning, collaboration, and expert guidance in navigating the dynamic ecosystem of ATMPs in Europe. 

Pardot Form
 
This article is intended to communicate Cencora’s capabilities which are backed by the authors’ expertise. However, Cencora strongly encourages readers to review all available information related to the topics discussed in this article and to rely on their own experience and expertise in making decisions related thereto.

 

White paper

The Inflation Reduction Act (IRA) and its implications for intellectual property incentives to develop drugs for select populations

Webinar

The Missing PIEce: Best Practices for Implementing Pre-Approval Information Exchange (PIE) in a Payer Communication Plan

Article

Interview: Evolving and expanding global consulting with local expertise

We’re here to help

Connect with our team today to learn more about how Cencora is helping to shape the future of healthcare.

Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.

Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.